On February 23, 2026, UiPath announced a suite of agentic AI solutions for healthcare providers and payers, targeting administrative and financial bottlenecks tied to revenue cycle management.
Opinion
Telcos try to hop on the AI train, Anthropic wars with the Pentagon, and agents threaten Microsoft
Telcos try to hop on the AI train, Anthropic wars with the Pentagon, and agents threaten Microsoft - SiliconANGLE ...
As elite UiPath Platinum Partner, Centelli gains expanded UiPath resources, training, and support, enabling enterprise-grade automations.
Detailed price information for Arista Networks Inc (ANET-N) from The Globe and Mail including charting and trades.
Australia’s insurance industry has crossed a decisive threshold. For the past decade, artificial intelligence has lived at ...
Agentic AI Foundation (AAIF) appoints David Nalley as governing board chair, and welcomes 18 new Gold Members and 79 new Silver Members. Under the AAIF, members help to reduce fragmentation in the ...
UiPath (NYSE:PATH) introduced new AI tools for healthcare at the ViVE 2026 conference. The offerings include medical records summarization, claim denial prevention, and prior authorization support.
Automation and artificial intelligence are often positioned as the antidote to clinician burnout and administrative overload. From ambient documentation to automated prior authorizations, the promise ...
The adoption of automation in software testing presents challenges that can hinder its effectiveness and scalability. This study systematically investigates these challenges using a multi-phase ...
UiPath's robotic process automation platform could be displaced by sophisticated AI tools. UiPath has embraced AI, integrating it into its platform and mitigating the downsides. UiPath could emerge as ...
UiPath is turning its agentic AI platform into a profitable growth engine. Alphabet's Gemini is one of the leading models benefiting from agentic AI adoption. Artificial intelligence (AI) adoption is ...
GENT, Belgium & MALVERN, Pa. & TOKYO--(BUSINESS WIRE)--#IVD--H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 CSF assay ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results